With current approved IBD therapeutics only effective in 20-25% of patients and often causing adverse side effects, pharma and biotech are aspiring to deliver clinical remission in 60-70% of patients and achieve more gut-selective compounds to minimise toxicity.
That being said, leading drug developers are telling us they are frustrated with limited innovation in preclinical models specifically for companies investing in antigen-specific candidates, and a lack of support to address patient recruitment in such a competitive landscape.
With over 50 gastroenterology, immunology and inflammation drug developers coming together to capitalise on the opportunity to discuss overcoming challenges limiting R&D and seek partnerships with organisations, GIIDS is your opportunity to put your service at the front of their minds.
GIIDS is a unique platform for you to showcase your solutions, generate new business leads and source opportunities for partnerships for 2019/2020 business development.
Email Sponsor@hansonwade.com for more information about the partnership opportunities available which will deliver on your commercial objectives this year.